09:28 AM EDT, 10/14/2025 (MT Newswires) -- Krystal Biotech ( KRYS ) said Tuesday that the US Food and Drug Administration has granted platform technology designation to the genetically modified, non-replicating herpes simplex virus type 1, or HSV-1, viral vector used in Krystal's eye drop gene therapy KB801.

KB801 is under assessment in a trial to treat neurotrophic keratitis, the company said.

"We are excited to work with the FDA under this program to identify potential efficiencies, including opportunities to leverage our prior experience with FDA-approved [Vyjuvek] to accelerate the development of our genetic medicines pipeline, starting with KB801 for the treatment of [neurotrophic keratitis,]" said Suma Krishnan, president of research and development at Krystal.